Patent · US Active

Monoclonal antibodies with enhanced ADCC function

US8685725B2 · kind B2 · utility

19Cited by

4References

26Claims

0Family size

Assignee

Laboratoire Francais du Fractionnement et des Biotechnologies · FR

Inventors

Roland Beliard · Santes, FR
Dominique Bourel · La Madeleine, FR
Arnaud Glacet · Gondecourt, FR
Christophe De Romeuf · Lille, FR
Nicolas Bihoreau · Orsay, FR
Emmanuel Nony · Antony, FR

Key dates

Filing date	Mar 31, 2011
Grant date	Apr 1, 2014
Priority date	—
Expiry date	Mar 31, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/732
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.